An estimated 18,000 people in the United States annually suffer from new injuries to their spinal cords. Unfortunately for ...

A recent publication in Genes & Diseases has delivered a compelling synthesis of the latest insights into the cellular ...

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...

Relay Therapeutics, Inc.’s RLAY share price has surged by 5.63%, which has investors questioning if this is right time to sell.

Dizal will also present results from the ongoing Phase I/II study of DZD6008, a 4th generation EGFR TKI with full BBB penetration, in advanced EGFR mutation positive (EGFRm) non-small cell lung cancer ...

The phosphoinositide 3-kinase (PI3K) pathway is a crucial signal transduction system linking the activation of receptor tyrosine kinases ... frequently activated signalling pathways in human ...

For one, microglia hovering around plaques—the type that express the most TREM2—reportedly become desensitized to stimulation ...

Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for VITRAKVI® (larotrectinib), a first-in-class TRK inhibitor for the treatment of adult and pediatric ...

Nurix is eligible for an additional $420 million in development, regulatory and commercial milestones associated with the ...

Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm autoimmune hemolytic anemia and IgG4-related disease.

In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.